Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
04:01pm, Friday, 07'th Feb 2025
THOUSAND OAKS, Calif. , Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m.
23 Upcoming Dividend Increases, Including 2 Kings
10:18am, Friday, 07'th Feb 2025
Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indica
Amgen: Multiple Strengths, But The Valuation Is A Concern
04:11am, Friday, 07'th Feb 2025
Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as a ho
Amgen Stock Has Surged. Here's Where It's Headed Next.
04:17pm, Thursday, 06'th Feb 2025
The stock is up 15% since late December.
Amgen: The Charts Didn't Lie, Upgrade To Buy
03:39pm, Thursday, 06'th Feb 2025
Amgen is a "buy" due to its strong earnings beat, attractive dividend, and technical chart pattern forecasting positive future performance. I prioritize a balanced approach, focusing on risk and rewar
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
07:37am, Thursday, 06'th Feb 2025
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. The company faces significant patent expiries but aims to offset losses with
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
03:08pm, Wednesday, 05'th Feb 2025
Amgen Inc.'s Q4 2024 earnings beat expectations, with 11% YoY revenue growth and 13% EPS increase, showcasing robust performance for the company's growth strategy. Amgen's diversified portfolio includ
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
12:21pm, Wednesday, 05'th Feb 2025
On Tuesday, Amgen Inc AMGN reported fourth-quarter sales of $9.10 billion, up 11% year-over-year, beating the consensus of $8.9 billion.
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
11:55am, Wednesday, 05'th Feb 2025
AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.
Amgen, Inc. (AMGN) Q4 2024 Earnings Call Transcript
08:32pm, Tuesday, 04'th Feb 2025
Amgen, Inc. (NASDAQ:AMGN ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Globa
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
08:30pm, Tuesday, 04'th Feb 2025
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
06:11pm, Tuesday, 04'th Feb 2025
Amgen (AMGN) came out with quarterly earnings of $5.31 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $4.71 per share a year ago.
Amgen Surpasses Q4 Earnings Forecasts
05:04pm, Tuesday, 04'th Feb 2025
Biotechnology specialist Amgen (AMGN 0.05%) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of $5.
Amgen shares sink despite quarterly beat, FDA places obesity drug on clinical hold
04:31pm, Tuesday, 04'th Feb 2025
CNBC's Angelica Peebles joins 'Closing Bell Overtime' with Amgen earnings.
Amgen profit beats estimates, next MariTide studies start by mid-year
04:06pm, Tuesday, 04'th Feb 2025
Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators
